CO2017009061A2 - Polipéptidos variantes de la enzima de degradación de inmunoglobulina g del s. pyogenes - Google Patents
Polipéptidos variantes de la enzima de degradación de inmunoglobulina g del s. pyogenesInfo
- Publication number
- CO2017009061A2 CO2017009061A2 CONC2017/0009061A CO2017009061A CO2017009061A2 CO 2017009061 A2 CO2017009061 A2 CO 2017009061A2 CO 2017009061 A CO2017009061 A CO 2017009061A CO 2017009061 A2 CO2017009061 A2 CO 2017009061A2
- Authority
- CO
- Colombia
- Prior art keywords
- pyogenes
- variant polypeptides
- degradation enzyme
- igg
- immunoglobulin
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 102000004190 Enzymes Human genes 0.000 title 1
- 108090000790 Enzymes Proteins 0.000 title 1
- 108060003951 Immunoglobulin Proteins 0.000 title 1
- 241000193996 Streptococcus pyogenes Species 0.000 title 1
- 230000015556 catabolic process Effects 0.000 title 1
- 238000006731 degradation reaction Methods 0.000 title 1
- 102000018358 immunoglobulin Human genes 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- 102000005927 Cysteine Proteases Human genes 0.000 abstract 1
- 108010005843 Cysteine Proteases Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
- C12N9/54—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea bacteria being Bacillus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201502306A GB201502306D0 (en) | 2015-02-12 | 2015-02-12 | Protein |
| PCT/EP2016/053052 WO2016128558A1 (en) | 2015-02-12 | 2016-02-12 | Cysteine protease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2017009061A2 true CO2017009061A2 (es) | 2018-01-16 |
Family
ID=52781456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2017/0009061A CO2017009061A2 (es) | 2015-02-12 | 2017-09-04 | Polipéptidos variantes de la enzima de degradación de inmunoglobulina g del s. pyogenes |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US10696959B2 (enExample) |
| EP (2) | EP4108768A1 (enExample) |
| JP (1) | JP6961486B2 (enExample) |
| KR (1) | KR102524613B1 (enExample) |
| CN (2) | CN114231512B (enExample) |
| AU (2) | AU2016217800B2 (enExample) |
| BR (1) | BR112017017284A2 (enExample) |
| CA (1) | CA2976003A1 (enExample) |
| CL (1) | CL2017002065A1 (enExample) |
| CO (1) | CO2017009061A2 (enExample) |
| DK (1) | DK3256580T3 (enExample) |
| EA (1) | EA035130B1 (enExample) |
| ES (1) | ES2927234T3 (enExample) |
| GB (1) | GB201502306D0 (enExample) |
| IL (1) | IL253938B (enExample) |
| LT (1) | LT3256580T (enExample) |
| MX (1) | MX390806B (enExample) |
| MY (1) | MY188696A (enExample) |
| PL (1) | PL3256580T3 (enExample) |
| PT (1) | PT3256580T (enExample) |
| SG (1) | SG11201706346QA (enExample) |
| WO (1) | WO2016128558A1 (enExample) |
| ZA (1) | ZA201705113B (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201413240D0 (en) * | 2014-07-25 | 2014-09-10 | Hansa Medical Ab | Method |
| GB201502306D0 (en) * | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
| GB201502305D0 (en) | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
| US20210228738A1 (en) | 2017-07-17 | 2021-07-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
| WO2019195423A1 (en) | 2018-04-03 | 2019-10-10 | Stridebio, Inc. | Virus vectors for targeting ophthalmic tissues |
| JP7406677B2 (ja) | 2018-04-03 | 2023-12-28 | ギンコ バイオワークス インコーポレイテッド | 抗体を回避するウイルスベクター |
| WO2019195444A1 (en) | 2018-04-03 | 2019-10-10 | Stridebio, Inc. | Antibody-evading virus vectors |
| AR118465A1 (es) | 2019-03-21 | 2021-10-06 | Stridebio Inc | Vectores de virus adenoasociados recombinantes |
| US12544437B2 (en) | 2019-10-04 | 2026-02-10 | Ultragenyx Pharmaceutical Inc. | Methods for improved therapeutic use of recombinant AAV |
| KR20220083708A (ko) | 2019-10-17 | 2022-06-20 | 스트라이드바이오 인코포레이티드 | Aav 전달 카세트 |
| AU2020367532A1 (en) | 2019-10-17 | 2022-05-12 | Ginkgo Bioworks, Inc. | Adeno-associated viral vectors for treatment of Niemann-Pick disease type C |
| KR20240007293A (ko) | 2019-12-06 | 2024-01-16 | 리제너론 파아마슈티컬스, 인크. | 항-vegf 단백질 조성물 및 이를 생산하는 방법 |
| GB202002072D0 (en) | 2020-02-14 | 2020-04-01 | Hansa Biopharma AB | immunoglobulin detection and associated therapies |
| BR112022015921A2 (pt) | 2020-02-14 | 2022-10-04 | Ultragenyx Pharmaceutical Inc | Terapia gênica para tratar o transtorno de deficiência de cdkl5 |
| GB202003129D0 (en) * | 2020-03-04 | 2020-04-15 | Hansa Biopharma AB | Conditioning regimen for transplant of stem cells |
| MX2022013812A (es) | 2020-05-08 | 2022-12-15 | Regeneron Pharma | Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer. |
| GB202007431D0 (en) * | 2020-05-19 | 2020-07-01 | Hansa Biopharma AB | Cysteine protease |
| GB202007434D0 (en) | 2020-05-19 | 2020-07-01 | Hansa Biopharma AB | Methods |
| US20230277633A1 (en) | 2020-06-05 | 2023-09-07 | Shanghai Bao Pharmaceuticals Co., Ltd. | Pharmaceutical composition of enzymes and viruses and application thereof |
| CN118562771A (zh) * | 2020-06-18 | 2024-08-30 | 上海宝济药业股份有限公司 | 一种免疫球蛋白降解酶IdeE的突变体 |
| MX2023002016A (es) | 2020-08-19 | 2023-06-26 | Sarepta Therapeutics Inc | Vectores de virus adenoasociados para el tratamiento del sindrome de rett. |
| WO2022076556A2 (en) | 2020-10-07 | 2022-04-14 | Asklepios Biopharmaceutical, Inc. | Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy disorders including limb girdle 2i (lgmd2i) |
| CA3216491A1 (en) | 2021-04-16 | 2022-10-20 | Asklepios Biopharmaceutical, Inc. | Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response |
| EP4079848A1 (en) | 2021-04-22 | 2022-10-26 | Genovis Ab | Immunoglobulin cleaving enzyme |
| JP2024531138A (ja) | 2021-08-11 | 2024-08-29 | ウルトラジェニックス ファーマシューティカル インコーポレイテッド | 筋ジストロフィーを処置するための組成物および方法 |
| WO2023084095A2 (en) | 2021-11-15 | 2023-05-19 | Hansa Biopharma AB | Methods for enhancing adoptive cell transfer immunotherapies |
| EP4450081A4 (en) | 2021-12-16 | 2025-05-07 | Shanghai Bao Pharmaceuticals Co., Ltd. | Anti-immunoglobulin-degrading enzyme-fermented FC variant |
| JP2024547125A (ja) | 2021-12-22 | 2024-12-26 | 上海宝済薬業股▲ふん▼有限公司 | 免疫グロブリン分解酵素ＩｄｅＥの変異体の用途 |
| EP4275701A1 (en) | 2022-05-13 | 2023-11-15 | Hansa Biopharma AB | Conditioning regimen for cell transplant |
| EP4302770A1 (en) | 2022-07-08 | 2024-01-10 | Hansa Biopharma AB | Regimen for enzymatic desensitisation |
| EP4349365A1 (en) | 2022-10-07 | 2024-04-10 | Hansa Biopharma AB | Co-treatment for gene therapy |
| CN118853710A (zh) * | 2022-11-08 | 2024-10-29 | 上海泰昶生物技术有限公司 | 生产免疫球蛋白g降解酶的工程菌株和工艺 |
| CN115998690B (zh) * | 2022-11-10 | 2024-07-26 | 上海泰昶生物技术有限公司 | 包含免疫球蛋白g降解酶的冻干制剂及其制备工艺 |
| WO2024108137A2 (en) | 2022-11-18 | 2024-05-23 | Seismic Therapeutic, Inc. | Fc fusion molecules and uses thereof |
| JP2026501731A (ja) | 2023-01-06 | 2026-01-16 | サイズミック セラピューティク インコーポレイテッド | プロテアーゼ変異体及びその使用 |
| WO2025072144A1 (en) * | 2023-09-27 | 2025-04-03 | Osprey Biopharmaceuticals, Inc. | Polypeptides having human igg cleavage activity |
| WO2025256977A1 (en) | 2024-06-13 | 2025-12-18 | Bayer Aktiengesellschaft | Novel igm and igg cleaving enzymes |
| WO2025256978A1 (en) | 2024-06-13 | 2025-12-18 | Bayer Aktiengesellschaft | Variants of igm and igg cleaving enzymes |
| GB202413764D0 (en) | 2024-09-18 | 2024-10-30 | Genovis Ab | Immunoglobulin proteases and their uses |
| GB202414654D0 (en) | 2024-10-04 | 2024-11-20 | Hansa Biopharma AB | Regimen for vector-based therapies |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US6800744B1 (en) * | 1997-07-02 | 2004-10-05 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics |
| US7595057B2 (en) | 2000-12-21 | 2009-09-29 | Id Biomedical Corporation | Streptococcus pyogenes antigens and corresponding DNA fragments |
| GB0130228D0 (en) * | 2001-12-18 | 2002-02-06 | Hansa Medica Ab | Protein |
| WO2004050116A1 (ja) * | 2002-11-29 | 2004-06-17 | Morinaga Milk Industry Co., Ltd. | プロテアーゼ阻害剤 |
| EP1601770B1 (en) * | 2003-03-04 | 2009-09-02 | Intercell AG | Streptococcus pyogenes antigens |
| WO2006131347A2 (en) * | 2005-06-09 | 2006-12-14 | Hansa Medical Ab | Use of the ides proteinase (from s. pyogenes) for treating autoimmune diseases and graft rejection |
| GB0511769D0 (en) * | 2005-06-09 | 2005-07-20 | Hansa Medical Ab | Treatment |
| US7544577B2 (en) * | 2005-08-26 | 2009-06-09 | International Business Machines Corporation | Mobility enhancement in SiGe heterojunction bipolar transistors |
| JP5722627B2 (ja) * | 2007-09-14 | 2015-05-27 | ジェノビス エービー | ＦＣガンマ受容体−ＩｇＧ複合体の解離、ならびにＩｇＧの精製および検出のための方法およびキット |
| AU2008336295B2 (en) | 2007-12-13 | 2013-07-11 | Intervacc Ab | Improved immunizing composition |
| CA2709029A1 (en) | 2007-12-21 | 2009-07-02 | Bianca Eser | Stability testing of antibodies |
| ES2535963T3 (es) * | 2009-02-09 | 2015-05-19 | Roche Glycart Ag | Análisis del patrón de glicosilación de inmunoglobulina |
| US9333252B2 (en) | 2010-05-26 | 2016-05-10 | Intervacc Ab | Vaccine against streptococcal infections based on recombinant proteins |
| GB201115841D0 (en) * | 2011-09-13 | 2011-10-26 | Genovis Ab | Protein and method |
| GB201201314D0 (en) | 2012-01-26 | 2012-03-07 | Isis Innovation | Composition |
| CN103214549B (zh) * | 2013-01-15 | 2015-08-05 | 珠海市丽珠单抗生物技术有限公司 | 一种还原免疫球蛋白的方法及其试剂盒 |
| GB201316744D0 (en) | 2013-09-20 | 2013-11-06 | Genovis Ab | Method |
| GB201413240D0 (en) | 2014-07-25 | 2014-09-10 | Hansa Medical Ab | Method |
| GB201502306D0 (en) * | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
| GB201502305D0 (en) * | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
-
2015
- 2015-02-12 GB GB201502306A patent/GB201502306D0/en not_active Ceased
-
2016
- 2016-02-12 EP EP22174919.5A patent/EP4108768A1/en active Pending
- 2016-02-12 CA CA2976003A patent/CA2976003A1/en active Pending
- 2016-02-12 BR BR112017017284A patent/BR112017017284A2/pt not_active Application Discontinuation
- 2016-02-12 KR KR1020177025560A patent/KR102524613B1/ko active Active
- 2016-02-12 MY MYPI2017001124A patent/MY188696A/en unknown
- 2016-02-12 CN CN202111557859.9A patent/CN114231512B/zh active Active
- 2016-02-12 EA EA201791773A patent/EA035130B1/ru not_active IP Right Cessation
- 2016-02-12 MX MX2017010390A patent/MX390806B/es unknown
- 2016-02-12 LT LTEPPCT/EP2016/053052T patent/LT3256580T/lt unknown
- 2016-02-12 AU AU2016217800A patent/AU2016217800B2/en active Active
- 2016-02-12 DK DK16707653.8T patent/DK3256580T3/da active
- 2016-02-12 SG SG11201706346QA patent/SG11201706346QA/en unknown
- 2016-02-12 US US15/550,309 patent/US10696959B2/en active Active
- 2016-02-12 CN CN201680021601.8A patent/CN107532156A/zh active Pending
- 2016-02-12 JP JP2017542896A patent/JP6961486B2/ja active Active
- 2016-02-12 WO PCT/EP2016/053052 patent/WO2016128558A1/en not_active Ceased
- 2016-02-12 ES ES16707653T patent/ES2927234T3/es active Active
- 2016-02-12 PT PT167076538T patent/PT3256580T/pt unknown
- 2016-02-12 PL PL16707653.8T patent/PL3256580T3/pl unknown
- 2016-02-12 EP EP16707653.8A patent/EP3256580B1/en active Active
-
2017
- 2017-07-27 ZA ZA2017/05113A patent/ZA201705113B/en unknown
- 2017-08-10 IL IL253938A patent/IL253938B/en active IP Right Grant
- 2017-08-11 CL CL2017002065A patent/CL2017002065A1/es unknown
- 2017-09-04 CO CONC2017/0009061A patent/CO2017009061A2/es unknown
-
2020
- 2020-05-20 US US16/879,324 patent/US11214784B2/en active Active
-
2021
- 2021-11-11 AU AU2021266293A patent/AU2021266293B2/en active Active
- 2021-12-14 US US17/644,315 patent/US11667905B2/en active Active
-
2023
- 2023-05-16 US US18/318,455 patent/US12359183B2/en active Active
-
2025
- 2025-06-09 US US19/232,657 patent/US20250304937A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017009060A2 (es) | Polipéptido hibrido de la enzima de degradación inmunoglobulina g del s. pyogenes y enzima de degradación de inmunoglobulina g del streptococcus equi ssp. zooepidemicus | |
| MX390806B (es) | Proteasa de cisteina. | |
| EA201792583A1 (ru) | Способы и композиции для ингибирования взаимодействия менина с белками mll | |
| GEP20217326B (en) | Constructs having a sirp-alpha domain or variant thereof | |
| BR112017024384A2 (pt) | bactérias modificadas para reduzir hiperfenilalaninemia | |
| MX391159B (es) | Proteínas de unión al antígeno anti-tigit y métodos para usarlas | |
| UY36905A (es) | Anticuerpos neutralizantes de poliomavirus | |
| MX2017014822A (es) | Composiciones y métodos para la reprogramación del tcr con proteínas de fusión. | |
| CO2017005784A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| MX2019008359A (es) | Cadena j modificada. | |
| MX2016009625A (es) | Proteinas quimericas tipo fosfatasa alcalina. | |
| MX2020005567A (es) | Metodos de tratamiento con asparaginasa. | |
| BR112016028891A2 (pt) | processos de trens de sementes e usos dos mesmos | |
| CO2017007121A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| EA201692529A1 (ru) | Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов | |
| MX2016013803A (es) | Manufactura de neurotoxinas del clostridium botulinum recombinantes. | |
| ECSP17003946A (es) | Anticuerpos antagonistas del interferón alfa y omega | |
| CR20160561A (es) | Variantes del anticuerpo anti-factor d y sus usos | |
| MX2017002469A (es) | Composiciones de matrices extracelulares. | |
| MX373805B (es) | Agonistas de receptor fgf21 y usos del mismo. | |
| CL2018002898A1 (es) | Nuevos anticuerpos anti-sirpa y sus aplicaciones terapéuticas. | |
| MX2017002796A (es) | Tasimelteon para tratar el sindrome de smith-magenis. | |
| BR112017024908A2 (pt) | usos terapêuticos da 4-cloroquinurenina | |
| BR112016019389A8 (pt) | Vacina, e, peptídeo | |
| CL2019000702A1 (es) | Anticuerpos anti-gm-csf y usos de los mismos. |